IMM Immupharma Plc

    RNS Number : 0898Y
  Immupharma PLC
  02 July 2008
   

 For Immediate Release  2 July 2008

        
    ImmuPharma PLC

    Long term toxicology studies confirmed the safety of LupuzorTM

    ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today
LupuzorTM its treatment for Lupus, a chronic, life-threatening autoimmune disease, completed the first leg of the mandatory long term
toxicology study package. International regulations require two long term toxicology studies (6 and 9 months) for drug products intended to
be use chronically. ImmuPharma reports that the first study has been completed and that there was no clinical or laboratory findings
suggesting any safety issues. Further, an interim analysis of the second study supported these findings. These studies were requirements
from The FDA (Food and Drug Administration) in the US prior to initiating ImmuPharma's Phase III programme.


    For further information please contact: 
 ImmuPharma PLC: 
 Dimitri Dimitriou, Chief Executive Officer              +44 20 7152 4080
 Dr Robert Zimmer, President & Chief Scientific Officer  + 33 389 32 76 50
 Richard Warr, Chairman                                  +44 20 7152 4080

 Buchanan Communications                                 + 44 20 7466 5000
 Lisa Baderoon
 Rebecca Skye Dietrich

 Panmure Gordon & Co
 Andrew Burnett                                          +44 151 243 0963


    For further company information, visit www.immupharma.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCRBMBTMMTMTFP

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024

Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024